BREAKING NEWS:Cellceutix is pleased to announce that success in its Phase 1 trial of super drug Kevetrin has caused a plethora of buyout offers from many of the worlds leading pharmaceutical companies. In what appears to be an unprecedented turn of events, Cellceutix (with the financial backing of un-named sources) has decided to buy all of its suitors and create the worlds foremost drug company... Cellphizrochecelgenylitics. The new company will combine the talents and resources of each company and will be led by CEO Leo Ehrlich. Common shares for the new company will be valued at $800 with Cellceutix shareholders receiving 5 new shares for each CTIX share because of the unprecedented value of Kevetrin. When asked to comment on the news, Mr Ehrlich said, "I told shareholders the best was yet to come!"

More news as it doesn't happen....